Liquidia Corporation (NASDAQ:LQDA) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Jason Adair - SVP, Corporate Development and Strategy Roger Jeffs - CEO Rajeev Saggar - CMO Rusty Schundler - General Counsel Mike Kaseta - CFO Conference Call Participants Gregory Harrison - Bank of America Kambiz Yazdi - Jefferies Serge Belanger - Needham Julian Harrison - BTIG Matt Kaplan - Ladenburg Thalmann Operator Good morning, and welcome, everyone, to the Liquidia Corporation's Full Ye ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in Its Charter) | Delaware | 85-1710962 | ...

Liquidia Corporation (NASDAQ:LQDA) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Jason Adair – Senior Vice President-Corporate Development and Strategy Roger Jeffs – Chief Executive Officer Rusty Schundler – General Counsel Mike Kaseta – Chief Financial Officer Rajeev Saggar – Chief Medical Officer Conference Call Participants Greg Harrison – Bank of America Chris Howerton – Jefferies Julian Harris – BTIG Matt Kaplan – Ladenburg Serge Belanger – Needham & Company Operato ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in Its Charter) | Delaware | 85-1710962 | | -- ...

Liquidia Corporation (NASDAQ:LQDA) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Jason Adair - Senior Vice President, Corporate Development and Strategy Roger Jeffs - Chief Executive Officer Dr. Rajeev Saggar - Chief Medical Officer Rusty Schundler - General Counsel Mike Kaseta - Chief Financial Officer Conference Call Participants Greg Harrison - Bank of America Serge Belanger - Needham & Company Matt Kaplan - Ladenburg Thalmann Julian Harrison - BTIG Operator Good mornin ...

Financial Performance - Revenue for the three months ended March 31, 2022, was $3.492 million, an increase of 13.3% compared to $3.084 million for the same period in 2021[17]. - Total costs and expenses for the same period were $17.964 million, up 48.5% from $12.085 million in the prior year[17]. - The net loss for the three months ended March 31, 2022, was $15.943 million, compared to a net loss of $9.183 million for the same period in 2021, reflecting a 73.5% increase in losses[17]. - For the three months ended March 31, 2022, Liquidia Corporation reported a net loss of $15.9 million, compared to a net loss of $9.2 million for the same period in 2021[21]. - Liquidia's cash used in operating activities for Q1 2022 was $9.8 million, a decrease from $12.4 million in Q1 2021[21]. Cash and Cash Equivalents - Cash and cash equivalents as of March 31, 2022, were $57.794 million, slightly up from $57.494 million at the end of 2021[16]. - Cash and cash equivalents as of March 31, 2022, were $57.8 million, an increase from $53.6 million at the end of Q1 2021[21]. - Liquidia anticipates that its cash and cash equivalents will be sufficient to fund operations into 2024[29]. Expenses - Research and development expenses decreased to $4.728 million in Q1 2022 from $6.054 million in Q1 2021, a reduction of 21.9%[17]. - General and administrative expenses surged to $12.542 million in Q1 2022, up 134.5% from $5.337 million in Q1 2021[17]. - The Company recorded total stock-based compensation expense of $4.185 million for the three months ended March 31, 2022, compared to $745,000 for the same period in 2021[89]. Liabilities and Deficits - The total liabilities increased to $38.136 million as of March 31, 2022, compared to $28.464 million at the end of 2021, marking a 33.9% rise[16]. - The accumulated deficit as of March 31, 2022, was $325.524 million, compared to $309.581 million at the end of 2021, indicating an increase in the deficit[16]. - Long-term debt increased to $19.476 million as of March 31, 2022, from $10.410 million as of December 31, 2021[113]. Revenue Sources - The company generated revenue primarily from a promotion agreement with Sandoz, which accounted for 98% of revenue and accounts receivable for the three months ended March 31, 2022[39]. - The Company derived approximately 98% of its revenue from the Promotion Agreement with Sandoz during the three months ended March 31, 2022[100]. Product Development and Commercialization - The company has plans to commercialize its product candidates and is actively pursuing regulatory approvals, including for YUTREPIA[11]. - Liquidia's lead product candidate, YUTREPIA, is designed to improve the therapeutic profile of treprostinil and received tentative FDA approval in November 2021[25]. - The company expects to incur significant expenses and operating losses for the foreseeable future as it seeks regulatory approval and pursues commercialization of its product candidates[26]. Stock and Equity - The company reported a weighted average of 52,465,283 common shares outstanding for the three months ended March 31, 2022, compared to 43,443,361 shares for the same period in 2021[17]. - The Company had 1,700,000 shares initially authorized for the 2020 Long-Term Incentive Plan, which increased by 2,091,509 shares on January 1, 2022, under the Evergreen Provision[78]. - The Company granted 409,569 time-based Restricted Stock Units (RSUs) during the three months ended March 31, 2022, with a weighted average grant-date fair value of $6.08[96]. Financing Activities - The company has financed its growth through a combination of revenue, stock issuances, and debt financing[27]. - The Company completed a private placement on April 13, 2021, raising approximately $21.7 million from the sale of 8,626,037 shares at $2.52 per share[75]. - The Company raised approximately $53.7 million in net proceeds from an underwritten public offering of 11,274,510 shares at an offering price of $5.10 per share[126]. Legal and Compliance - The company’s litigation finance payable is classified as a long-term liability, reflecting ongoing legal expenses related to litigation[68]. - The company adopted ASU 2020-06 effective January 1, 2022, which had no impact on its financial statements[55].

Liquidia Corporation(NASDAQ:LQDA) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Jason Adair - SVP, Corporate Development and Strategy Roger Jeffs - CEO Mike Kaseta - CFO Rusty Schundler - General Counsel Conference Call Participants Serge Belanger - Needham & Company Julian Harrison - BTIG Andreas Argyrides - Wedbush Operator Good morning, and welcome, everyone, the Liquidia Corporation First Quarter 2022 Financial Results and Corporate Update Conference Call. My name is Howa ...

Table of Contents | UNITED STATES | | | --- | --- | | SECURITIES AND EXCHANGE COMMISSION | | | Washington, D.C. 20549 | | | FORM 10-K | | | (Mark One) | | | ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the fiscal year ended December 31, 2021 | | | or | | | ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF | | | 1934 | | | For the transition period from to | | | Commission File Number: 001-39724 | | | LIQUIDIA CORPORATION ...

Liquidia Corporation (NASDAQ:LQDA) Q4 2021 Earnings Conference Call March 17, 2022 8:30 AM ET Company Participants Jason Adair - SVP, Corporate Development and Strategy Roger Jeffs - CEO Mike Kaseta - CFO Rusty Schundler - General Counsel Conference Call Participants Kambiz Yazdi - Jefferies Serge Belanger - Needham & Company Andreas Argyrides - Wedbush Securities Julian Harrison - BTIG Operator Good morning and welcome everyone, to the Liquidia Corporation Full Year 2021 Financial Results and Corporate Upd ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in Its Charter) | Delaware | 85-1710962 | ...